HCW Biologics (NASDAQ:HCWB) Director Scott Garrett Purchases 177,936 Shares

Posted by Francis Steltz on May 28th, 2026

HCW Biologics Inc. (NASDAQ:HCWB – Get Free Report) Director Scott Garrett purchased 177,936 shares of HCW Biologics stock in a transaction that occurred on Friday, May 22nd. The shares were purchased at an average price of $1.41 per share, for a total transaction of $250,889.76. Following the transaction, the director directly owned 203,441 shares in the company, valued at $286,851.81. This represents a 697.65% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

HCW Biologics Trading Down 26.0%

NASDAQ HCWB opened at $1.94 on Thursday. The firm has a market capitalization of $13.06 million, a price-to-earnings ratio of -0.21 and a beta of 1.13. The firm’s 50 day simple moving average is $0.72 and its 200 day simple moving average is $1.15. HCW Biologics Inc. has a 1 year low of $0.25 and a 1 year high of $8.75.

HCW Biologics (NASDAQ:HCWB – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.81. The company had revenue of $6.54 million for the quarter, compared to analyst estimates of $6.54 million. HCW Biologics had a negative net margin of 34.73% and a negative return on equity of 486.87%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in HCW Biologics stock. Armistice Capital LLC acquired a new stake in HCW Biologics Inc. (NASDAQ:HCWB – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned 9.15% of HCW Biologics at the end of the most recent reporting period. Institutional investors own 2.96% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a report on Tuesday, April 21st. Wall Street Zen raised shares of HCW Biologics to a “hold” rating in a report on Saturday, May 23rd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, HCW Biologics currently has a consensus rating of “Hold” and a consensus price target of $35.00.

Get Our Latest Report on HCWB

HCW Biologics Company Profile

(Get Free Report)

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.